ASH News Daily 2017 - Issue 2 - B-37

80% ORR [95% CI: 72, 87] / 40% CR [95% CI: 31, 49] / IRC-assessed per 2014 Lugano classiﬁcation*/
Median DoR not reached at 15.2 month median follow-up

Atrial Fibrillation and Flutter
In the combined safety database of 612
patients with hematologic malignancies
treated with CALQUENCE monotherapy,
atrial ﬁbrillation and atrial ﬂutter of any
grade occurred in 3% of patients, and
Grade 3 in 1% of patients. Monitor for
atrial ﬁbrillation and atrial ﬂutter and
manage as appropriate.
ADVERSE REACTIONS
The most common adverse reactions
(≥20%) of any grade were anemia,*
thrombocytopenia,* headache (39%),
neutropenia,* diarrhea (31%), fatigue
(28%), myalgia (21%), and bruising
(21%).
*Treatment-emergent decreases (all
grades) of hemoglobin (46%), platelets
(44%), and neutrophils (36%) were
based on laboratory measurements
and adverse reactions.
The most common Grade ≥3
non-hematological adverse reaction
(reported in at least 2% of patients) was
diarrhea (3.2%).
Dosage reductions or discontinuations
due to any adverse reaction were reported
in 1.6% and 6.5% of patients, respectively.

Increases in creatinine 1.5 to 3 times the
upper limit of normal occurred in 4.8%
of patients.
DRUG INTERACTIONS
Strong CYP3A Inhibitors: Avoid
co-administration with a strong CYP3A
inhibitor. If a strong CYP3A inhibitor
will be used short-term, interrupt
CALQUENCE.
Moderate CYP3A Inhibitors: When
CALQUENCE is co-administered with
a moderate CYP3A inhibitor, reduce
CALQUENCE dose to 100 mg once daily.
Strong CYP3A Inducers: Avoid
co-administration with a strong CYP3A
inducer. If a strong CYP3A inducer cannot
be avoided, increase the CALQUENCE
dose to 200 mg twice daily.
Gastric Acid Reducing Agents: If
treatment with a gastric acid reducing
agent is required, consider using an
H2-receptor antagonist or an antacid.
Take CALQUENCE 2 hours before taking
an H2-receptor antagonist. Separate
dosing with an antacid by at least 2 hours.
Avoid co-administration with proton
pump inhibitors. Due to the long-lasting
effect of proton pump inhibitors,

separation of doses may not eliminate
the interaction with CALQUENCE.
SPECIFIC POPULATIONS
There is insufﬁcient clinical data on
CALQUENCE use in pregnant women to
inform a drug-associated risk for major
birth defects and miscarriage. Advise
women of the potential risk to a fetus.
It is not known if CALQUENCE is present
in human milk. Advise lactating
women not to breastfeed while taking
CALQUENCE and for at least 2 weeks after
the ﬁnal dose.
*Tumor response was assessed according to the Lugano
classiﬁcation for non-Hodgkin's lymphoma (NHL).

CR=complete response; DoR=duration of response;
IRC=Independent Review Committee; ORR=overall response
rate (deﬁned as the proportion of patients who achieved a CR
or PR); PR=partial response; R/R=relapsed/refractory.
Reference: 1. CALQUENCE [package insert]. Wilmington, DE:
AstraZeneca Pharmaceuticals LP; 2017.

VISIT CALQUENCE.COM/NEW

11/10/17 12:32 PM

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 2

ASH News Daily 2017 - Issue 2 - A-1
ASH News Daily 2017 - Issue 2 - A-2
ASH News Daily 2017 - Issue 2 - A-3
ASH News Daily 2017 - Issue 2 - A-4
ASH News Daily 2017 - Issue 2 - A-5
ASH News Daily 2017 - Issue 2 - A-6
ASH News Daily 2017 - Issue 2 - A-7
ASH News Daily 2017 - Issue 2 - A-8
ASH News Daily 2017 - Issue 2 - A-9
ASH News Daily 2017 - Issue 2 - A-10
ASH News Daily 2017 - Issue 2 - A-11
ASH News Daily 2017 - Issue 2 - A-12
ASH News Daily 2017 - Issue 2 - A-13
ASH News Daily 2017 - Issue 2 - A-14
ASH News Daily 2017 - Issue 2 - A-15
ASH News Daily 2017 - Issue 2 - A-16
ASH News Daily 2017 - Issue 2 - A-17
ASH News Daily 2017 - Issue 2 - A-18
ASH News Daily 2017 - Issue 2 - A-19
ASH News Daily 2017 - Issue 2 - A-20
ASH News Daily 2017 - Issue 2 - A-21
ASH News Daily 2017 - Issue 2 - A-22
ASH News Daily 2017 - Issue 2 - A-23
ASH News Daily 2017 - Issue 2 - A-24
ASH News Daily 2017 - Issue 2 - A-25
ASH News Daily 2017 - Issue 2 - A-26
ASH News Daily 2017 - Issue 2 - A-27
ASH News Daily 2017 - Issue 2 - A-28
ASH News Daily 2017 - Issue 2 - B-1
ASH News Daily 2017 - Issue 2 - B-2
ASH News Daily 2017 - Issue 2 - B-3
ASH News Daily 2017 - Issue 2 - B-4
ASH News Daily 2017 - Issue 2 - B-5
ASH News Daily 2017 - Issue 2 - B-6
ASH News Daily 2017 - Issue 2 - B-7
ASH News Daily 2017 - Issue 2 - B-8
ASH News Daily 2017 - Issue 2 - B-9
ASH News Daily 2017 - Issue 2 - B-10
ASH News Daily 2017 - Issue 2 - B-11
ASH News Daily 2017 - Issue 2 - B-12
ASH News Daily 2017 - Issue 2 - B-13
ASH News Daily 2017 - Issue 2 - B-14
ASH News Daily 2017 - Issue 2 - B-15
ASH News Daily 2017 - Issue 2 - B-16
ASH News Daily 2017 - Issue 2 - B-17
ASH News Daily 2017 - Issue 2 - B-18
ASH News Daily 2017 - Issue 2 - B-19
ASH News Daily 2017 - Issue 2 - B-20
ASH News Daily 2017 - Issue 2 - B-21
ASH News Daily 2017 - Issue 2 - B-22
ASH News Daily 2017 - Issue 2 - B-23
ASH News Daily 2017 - Issue 2 - B-24
ASH News Daily 2017 - Issue 2 - B-25
ASH News Daily 2017 - Issue 2 - B-26
ASH News Daily 2017 - Issue 2 - B-27
ASH News Daily 2017 - Issue 2 - B-28
ASH News Daily 2017 - Issue 2 - B-29
ASH News Daily 2017 - Issue 2 - B-30
ASH News Daily 2017 - Issue 2 - B-31
ASH News Daily 2017 - Issue 2 - B-32
ASH News Daily 2017 - Issue 2 - B-33
ASH News Daily 2017 - Issue 2 - B-34
ASH News Daily 2017 - Issue 2 - B-35
ASH News Daily 2017 - Issue 2 - B-36
ASH News Daily 2017 - Issue 2 - B-37
ASH News Daily 2017 - Issue 2 - B-38
ASH News Daily 2017 - Issue 2 - B-39
ASH News Daily 2017 - Issue 2 - B-40
ASH News Daily 2017 - Issue 2 - B-41
ASH News Daily 2017 - Issue 2 - B-42
ASH News Daily 2017 - Issue 2 - B-43
ASH News Daily 2017 - Issue 2 - B-44
ASH News Daily 2017 - Issue 2 - B-45
ASH News Daily 2017 - Issue 2 - B-46
ASH News Daily 2017 - Issue 2 - B-47
ASH News Daily 2017 - Issue 2 - B-48
ASH News Daily 2017 - Issue 2 - B-49
ASH News Daily 2017 - Issue 2 - B-50
ASH News Daily 2017 - Issue 2 - B-51
ASH News Daily 2017 - Issue 2 - B-52
ASH News Daily 2017 - Issue 2 - B-53
ASH News Daily 2017 - Issue 2 - B-54
ASH News Daily 2017 - Issue 2 - B-55
ASH News Daily 2017 - Issue 2 - B-56
ASH News Daily 2017 - Issue 2 - C-1
ASH News Daily 2017 - Issue 2 - C-2
ASH News Daily 2017 - Issue 2 - C-3
ASH News Daily 2017 - Issue 2 - C-4
ASH News Daily 2017 - Issue 2 - C-5
ASH News Daily 2017 - Issue 2 - C-6
ASH News Daily 2017 - Issue 2 - C-7
ASH News Daily 2017 - Issue 2 - C-8
ASH News Daily 2017 - Issue 2 - C-9
ASH News Daily 2017 - Issue 2 - C-10
ASH News Daily 2017 - Issue 2 - C-11
ASH News Daily 2017 - Issue 2 - C-12
ASH News Daily 2017 - Issue 2 - C-13
ASH News Daily 2017 - Issue 2 - C-14
ASH News Daily 2017 - Issue 2 - C-15
ASH News Daily 2017 - Issue 2 - C-16
ASH News Daily 2017 - Issue 2 - C-17
ASH News Daily 2017 - Issue 2 - C-18
ASH News Daily 2017 - Issue 2 - C-19
ASH News Daily 2017 - Issue 2 - C-20
ASH News Daily 2017 - Issue 2 - C-21
ASH News Daily 2017 - Issue 2 - C-22
ASH News Daily 2017 - Issue 2 - C-23
ASH News Daily 2017 - Issue 2 - C-24
ASH News Daily 2017 - Issue 2 - C-25
ASH News Daily 2017 - Issue 2 - C-26
ASH News Daily 2017 - Issue 2 - C-27
ASH News Daily 2017 - Issue 2 - C-28
ASH News Daily 2017 - Issue 2 - C-29
ASH News Daily 2017 - Issue 2 - C-30
ASH News Daily 2017 - Issue 2 - C-31
ASH News Daily 2017 - Issue 2 - C-32
https://www.nxtbookmedia.com